1 Bundesamt für Statistik / Nationales Institut für Krebsepidemiologie und -registrierung (NICER) – Krebs in der Schweiz 2011–2015 [Published:27.11.2018; Accessed: 29.02.2020]. Available from:
https://www.bfs.admin.ch/bfs/de/home/statistiken/gesundheit/gesundheitszustand/krankheiten/krebs.html
2 European Association of Urology. Muscle-invasive and Metastatic Bladder Cancer. Edn. presented at the EAU Annual Congress Barcelona 2019. [Accessed: 21.05.2019]. Available from:
https://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic
3 European Association of Urology. Non-muscle-invasive Bladder Cancer. Edn. presented at the EAU Annual Congress Barcelona 2019. [Accessed: 04.03.2020]. Available from:
https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/ 4 Hautmann RE, de Petriconi RC, Volkmer BG. Lessons learned from 1,000 neobladders: the 90-day complication rate. J Urol. 2010;184(3):990–4.
5 Smith AB, Jaeger B, Pinheiro LC, Edwards LJ, Tan HJ, Nielsen ME, et al. Impact of bladder cancer on health-related quality of life. BJU Int. 2018;121:549–57.
6 Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rödel CM, et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol. 2014;66:120–37.
7 Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up 2014; Ann Oncol. 2014 Sep;25 Suppl 3:iii40-8.
doi:10.1093/annonc/mdu223.
8 NCCN Clinical Practice Guidelines in Oncology - Bladder Cancer. Version 3.2018 [Published: 14.03.2018; Accessed: 15.05.2018]. Available from:
https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
9 Lebret T, Herve JM, Yonneau L, Molinie V, Barre P, Lugagne PM, et al. After cystectomy, is it justified to perform a bladder replacement for patients with lymph node positive bladder cancer? Eur Urol. 2002;42(4):344–9.
10 Bellmunt J, Petrylak DP. New therapeutic challenges in advanced bladder cancer. Semin Oncol. 2012;39:598–607.
11 Kulkarni GS, Hermanns T, Wei Y, Bhindi B, Satkunasivam R, Athanasopoulos P, et al. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. J Clin Oncol. 2017;35:2299–305.
12 James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366:1477–88.
13 Mitin T, George A, Zietman AL, Heney NM, Kaufman DS, Uzzo RG, et al. Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233. Int J Radiat Oncol Biol Phys. 2016;94:67–74.
14 Cohen SM, Goel A, Phillips J, Ennis RD, Grossbard ML. The role of perioperative chemotherapy in the treatment of urothelial cancer. Oncologist. 2006;11:630–40.
15 Williams SB, Shan Y, Ray-Zack MD, Hudgins HK, Jazzar U, Tyler DS, et al. Comparison of Costs of Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer. JAMA Surg. 2019 Jun 5:e191629.
doi:10.1001/jamasurg.2019.1629.
16 Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, et al. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. Eur Urol. 2017;72:544–54.